Press Releases

Date Title and Summary View
Nov 03, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in
Nov 02, 2021
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
Investigational New Drug (IND) application submitted for MGD024, a next generation DART ® molecule targeting CD123 and CD3 for AML U.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP manufacturing facility to produce MARGENZA ® drug substance Discontinuing enrollment of Cohort A of
Oct 26, 2021
MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD , Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Sep 16, 2021
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A 78% of patients had tumor shrinkage at first scan Median duration of response was 10.3 months as of data cutoff Margetuximab
Sep 16, 2021
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor activity; 4 of 16 (25%) achieved partial responses (two confirmed and two unconfirmed) Non-small cell
Sep 12, 2021
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
ROCKVILLE, MD , Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple
Sep 07, 2021
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm, while the OS
Sep 02, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Sept. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in
Aug 05, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
Jul 29, 2021
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) Meeting Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a biopharmaceutical company
Jul 22, 2021
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD , July 22, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Jun 16, 2021
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors Zai Lab provides rights to MacroGenics
May 19, 2021
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patients Cohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction; anti-tumor activity observed in four of seven patients evaluated (including one unconfirmed partial
May 19, 2021
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD , May 19, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in
Apr 29, 2021
MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results
MARGENZA™ launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCO Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , April 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing
Apr 19, 2021
MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD , April 19, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Apr 10, 2021
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
ROCKVILLE, MD , April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for
Feb 26, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Feb. 26, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate
Feb 25, 2021
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
MARGENZA™ approved in December 2020 ; commercial launch expected March 2021 July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab Multiple clinical updates across portfolio anticipated in 2021 Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md.
Feb 18, 2021
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
ROCKVILLE, MD , Feb. 18, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Feb 11, 2021
MacroGenics Names Federica O’Brien to its Board of Directors
ROCKVILLE, MD , Feb. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien,
Feb 11, 2021
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
ROCKVILLE, MD , Feb. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone has been achieved
Feb 08, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Feb. 08, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate
Jan 25, 2021
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb)   showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® ( trastuzumab), both with chemotherapy In the U.S. , MARGENZA is approved, in combination with chemotherapy, for the treatment of
Jan 11, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Jan. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc.  (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate